Decreased potency of fimasartan in liver cirrhosis was quantified using mixed-effects analysis

Fimasartan is a nonpeptide angiotensin II receptor blocker. In a previous study that compared the pharmacokinetics (PK) of fimasartan between patients with hepatic impairment (cirrhosis) and healthy subjects, the exposure to fimasartan was found to be higher in patients, but the decrease of blood pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Choon OK, Jeon, Sangil, Han, Seunghoon, Hong, Taegon, Park, Min Soo, Yoon, Young-Ran, Yim, Dong-Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Clinical Pharmacology and Therapeutics 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033533/
https://www.ncbi.nlm.nih.gov/pubmed/32095458
http://dx.doi.org/10.12793/tcp.2017.25.1.43

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033533/
https://www.ncbi.nlm.nih.gov/pubmed/32095458
http://dx.doi.org/10.12793/tcp.2017.25.1.43

Ejemplares similares